Noah Medical Reports Inaugural Deployment of the Galaxy System™ in Asia.

Noah Medical has made an announcement revealing that the inaugural utilization of its Galaxy surgical robot system in Asia took place at a hospital in Hong Kong. The first application of the Galaxy system in Asia was performed by Dr. Calvin Ng and Dr. Rainbow Lau at Prince of Wales Hospital, marking the commencement of the initial clinical trial for the robotic bronchoscopy system in the region.

San Carlos, California-based Noah Medical obtained FDA clearance for the Galaxy system in March. Following that, the company documented the initial commercial cases with the system in the United States in May.

The Galaxy system facilitates bronchoscopic visualization and access, allowing for diagnostic and therapeutic procedures within patient airways. Equipped with advanced imaging technologies, Galaxy provides real-time updates on the location of potentially cancerous lesions. Developed by Noah Medical, this technology aims to enhance tool-in-lesion capabilities and diagnostic yield, enabling physicians to confidently navigate and biopsy lung nodules.

“We are excited to be the first site in Asia to trial this exciting new technology,” said Ng. “The Galaxy System is the latest generation in robotic bronchoscopy and we are very much looking forward to seeing this being used in Hong Kong, and eventually the broader Asia region.”

Galaxy incorporates proprietary integrated tomosynthesis (TiLT+ Technology) with augmented fluoroscopy. With a disposable, single-use bronchoscope and a compact footprint, the system seamlessly integrates into most bronchoscopy suites.

Noah Medical anticipates that the Hong Kong trial will further validate its TiLT+ Technology, center-strike accuracy, and overall diagnostic yield. The initial patient enrollment has been successful, and the trial is currently in progress.

“Congratulations to Dr. Ng, Dr. Lau and the team at Prince of Wales Hospital for their continued efforts in bringing advanced robotic lung technologies to Asia,” said Jian Zhang, Noah Medical founder and CEO. “We are excited to explore the opportunity of early diagnosis and treatment of lung cancer globally, which will benefit billions of patients.

“Our mission, in concert with pioneers like Dr. Ng and Dr. Lau, is to help physicians diagnose and treat lung cancer more accurately and efficiently than ever before


© Noah Medical Inc.

Post a comment

Your email address will not be published. Required fields are marked *

Recent News

Successful completion of the inaugural shoulder arthroplasty surgeries utilizing Stryker’s Blueprint® Mixed Reality Guidance System occurred at Mayo Clinic in Minnesota and St. Joseph’s Health Care in London, Canada.

Medical Device Technologies Market is projected to increase from USD 4.20 Billion in 2022 to USD 16.32 Billion by 2030, reflecting a robust Compound Annual Growth Rate (CAGR) of 18.50% over the forecast period

Hodess Cleanroom Construction expands its cleanroom services capabilities with the acquisitions of Protocol Management Services and Clean Rooms West

Medtronic Will Invest Up to $75 Million And begin Co-Promotion For CathWorks’ FFRangio System In The U.S. Europe and Japan

Tornier Shoulder Arthroplasty Portfolio Introduced by Stryker, With New Tornier Perform Humeral System Launched in Europe